RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Addressing urgent unmet needs in rare diseases

At Hansa Biopharma, we are on a mission to develop innovative immunomodulatory treatments and bring them to those patients whose medical needs have been overlooked.

This is Hansa

One enzyme platform, many therapeutic opportunities

Our unique enzyme technology platform can transform the lives of people affected by rare immunologic conditions, by advancing scientific innovation in many disease areas.

Our technology platform

Empowering patients with innovative therapies

We are dedicated to developing lifesaving and life altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.

Therapeutic areas

    “We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological conditions.”

    Søren Tulstrup, President and CEO

    15

    Years of innovation

    10

    Clinical and preclinical programs

    +30

    Nationalities represented in our workforce

    Our Technology platform

    Our unique antibody-cleaving enzyme technology

    We have developed our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.

    Our technology platform

    Hansa story

    Empowering rare

    At Hansa, our ambition is to help empower patients with rare immunological conditions to live long and healthy lives. By developing innovative, lifesaving and life altering treatments and bringing them from the laboratory to the bedside of the patient, we strive to help address their unmet medical need.

    Media

    Our latest press releases

    Therapeutic Areas

    Our unique enzyme technology has the potential to transform the lives of people affected by rare immunologic conditions, including transplant rejection, genetic diseases, autoimmune conditions, and cancer.

    Melissa. Highly sensitized kidney patient on dialysis, USA.

    Sustainability

    We are the bigger picture

    Since 2007, we have been fully committed to those living with rare conditions and have worked to develop lifesaving and life altering therapies through pioneering research and innovation. We strive to live up to the high ethical standards we set for ourselves, and to be a force for good both for individuals and society as a whole.

    Our commitment

    Media

    News and insights

    Strategic Partnerships

    We partner to maximize the impact of our technology on patients’ lives

    We value collaboration with strategic partners as an important part in our mission to develop innovative treatments that can address the unmet needs of rare disease patients and we seek the best partnering opportunities to maximize the potential of our technology platform. Our technology has received external validation through multiple collaborations, and it could potentially be used in a variety of transplantation and autoimmune indications, and as a pre-treatment ahead of gene therapy.

    Partnering
    Meetings of interest

    Impactful interaction with the scientific and medical community

    At Hansa, we are focused on the bigger picture and want help rare disease patients live long and healthy lives. We do this also by constant engagement with the scientific and healthcare communities. We use this opportunity to not only raise awareness about the unmet needs of the patients, but also to help advance the understanding in these complex fields. Meetings of interest

    Ready for a new career? Join us

    Coffee and notepad

    E-mail

    Sign up to receive updates on the latest company news and filings

    Choose type

    Thank you. You will get an e-mail message to activate your subscription.